Tufts CSDD Free Whitepaper

Impact report: Decentralized/Hybrid Trials Deliver Greater ROI Than Traditional Trials

The Tufts Center for the Study of Drug Development completed an analysis of its financial modeling study of decentralized clinical trials  using real data from Medable-enabled studies. These findings net financial benefits ranging from 5x for Phase II and 13x for Phase III trials, equating to roughly $10 million ROI and $39 million ROI, respectively.

Expanding on the outcomes of the Tufts Paper, this Impact Report provides key insights on the findings of the study. Data available on the impact of DCT solutions show a reduction in three factors that can impact drug development financial value.

Read more in a Free download of the Impact Report.

Who is Tufts CSDD?

Tufts CSDD is an independent, academic, non-profit research center at Tufts University in Boston. Founded in 1976, the university is, dedicated to researching drug development.

Heading

Heading

Heading

Save the Date!
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
Learn why Tuft's research will transform your trials